Liver Transplant
Major abdominal operation that removes a diseased liver and replaces it with a deceased- or living-donor graft, indicated for end-stage liver disease and acute liver failure.
Overview
Hospital & stay
Procedure details
How it's performed
Under general anaesthesia and via an upper-abdominal hockey-stick or inverted-Y incision, the surgical team mobilises the cirrhotic liver, divides ligamentous attachments, and clamps the vena cava and portal vein before hepatectomy. The donor liver is then implanted with end-to-end anastomoses of the suprahepatic and infrahepatic IVC, the portal vein and the hepatic artery, with reperfusion in stages. Bile drainage is restored by direct duct-to-duct anastomosis or Roux-en-Y choledochojejunostomy. Drains are placed and the abdomen is closed.
Preparation
- 1Comprehensive transplant assessment: MELD/UKELD scoring, cardiac and pulmonary work-up, dental review, infection screen.
- 2Listing on the national transplant registry with regular re-evaluation; or living-donor work-up if relevant.
- 3Optimise nutrition (high-protein, branched-chain amino acids) and manage ascites, encephalopathy and varices.
- 4Vaccinations (hepatitis B, pneumococcus, influenza) before transplantation.
- 5Pre-operative bloods and cross-match; psychological preparation for lifelong immunosuppression.
Recovery
- 1Day 0-3: Intensive care monitoring, ventilator support, daily Doppler ultrasound of vascular anastomoses.
- 2Days 3-14: Step-down ward; initiation and titration of tacrolimus-based immunosuppression; physiotherapy.
- 3Weeks 2-4: Hospital discharge once graft function is stable, drains removed and patient self-caring.
- 4Weeks 4-12: Frequent outpatient blood tests, immunosuppression dosing, surveillance for rejection and infection.
- 5Months 3-6: Gradual return to office work; close monitoring of liver enzymes, drug levels and CMV.
- 6Lifelong: Annual review, cancer surveillance and lifelong immunosuppression.
Related procedures
Related procedures
Liver Transplantation: Outcomes, Donor Options and the Supporting Evidence
14 peer-reviewed sourcesLiver transplantation is the definitive treatment for end-stage liver disease and for selected liver cancers, and its outcomes are documented in large cohorts, registry analyses, meta-analyses and international guidance. Contemporary data show that transplantation is the major determinant of long-term survival in patients who would otherwise face progressive liver failure, with many recipients living well beyond ten years. Comparative studies of living-donor and deceased-donor transplantation report broadly comparable, and in some settings superior, recipient survival with living donation, alongside careful attention to donor safety. For hepatocellular carcinoma, transplant selection criteria continue to evolve beyond the original Milan thresholds, and network meta-analyses are refining how expanded criteria balance access against recurrence risk. The references below draw on outcome cohorts, comparative meta-analyses, standardized donor-evaluation protocols and selection-criteria research relevant to patients considering transplantation.
- Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma
- Meta-Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis
- Comparative Outcomes of Living and Deceased Donor Liver Transplantation in Adults: A Systematic Review and Meta-Analysis
- Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma and HCV Patients: An Initial Umbrella Review
- Liver Transplantation Versus Resection for Hepatocellular Carcinoma: An Umbrella and Meta-Meta-Analysis of Published Evidence, 2000-2025
Compiled from peer-reviewed medical literature indexed on PubMed. This overview is for general education and is not medical advice. · Last updated 2026-06-15